Rafael Holdings (RFL) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

RFL Rafael Holdings

Watchlist

1.590
-0.030-1.85%

Close Dec 27 16:00 ET

1.520
-0.070-4.40%

Post 19:43 ET

53.59MMarket Cap-0.95P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Rafael Holdings | 10-K/A: Annual report (Amendment)
SECDec 20 11:57 ET · Announcements
Rafael Holdings: Strategic Developments and Financial Insights
TipRanksDec 11 22:52 ET
Rafael Holdings | 10-Q: Q1 2025 Earnings Report
SECDec 11 07:40 ET · Announcements
Rafael Holdings, Inc. Reports First Quarter Fiscal Year 2025 Financial Results and Updates on Planned Merger With Cyclo Therapeutics
Quiver QuantitativeDec 11 07:15 ET
Rafael Holdings Reports Q1 EPS (37c) Vs (15c) Last Year
TipRanksDec 11 07:06 ET
Rafael Holdings Targets Vote on Cyclo Therapeutics Merger in 1Q>RFL
Dow JonesDec 11 07:03 ET

Comments

Meltyy

Oct 11 01:22

🚨 M&A Update! 🚨

Keep an eye on these recently announced & closed M&As: 👀
🟢 Recently Announced:
⇒ $Organon & Co (OGN.US)$ to acquire Dermavant
⇒ $Rafael Holdings (RFL.US)$ to acquire Cyclo Tx
⇒Crown Lab to acquire $Revance Therapeutics (RVNC.US)$
⇒ $Recursion Pharmaceuticals (RXRX.US)$ merger with Exscientia
🔴 Recently Closed:
⇒ $Johnson & Johnson (JNJ.US)$ acquired V-Wave
⇒ Pharmacosmos acquired $GTHX
What companies will be next? 🤔

Trytosaveabit

Aug 22 05:53

Update

$Cyclo Therapeutics (CYTH.US)$ $Rafael Holdings (RFL.US)$ Rafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger Agreement
Cyclo Therapeutics' TransportNPC(TM) Phase 3 clinical trial for Trappsol(R) Cyclo(TM) for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025
NEWARK, N.J. and GAINESVILLE, Fla., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Rafael Holdings, I...